Navigation Links
Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar

Tracy Worzella and Brad Larson
Promega Corporation, Madison, WI, USA

Application Note 139 Rev. 7/2006

  • Multiplexing homogeneous cell-based assays for analysis of different parameters from a single sample well
  • Monitoring of reporter gene activity and cell viability
  • Assay miniaturization up to 1536-well format

  • Introduction
    Today's high-throughput screening facilities face increasing demands to generate more information from their existing compound libraries. One method of obtaining this information is to run assays sequentially, looking at one parameter followed by another in different plates. While this option may produce the desired data, the increased time and consumable costs are drawbacks. A more appealing method for data generation is to perform assays in a multiplexed format in which several parameters can be measured within the same well. This multiplexed format not only saves time and consumable cost, but also saves on the useage of valuable test compounds.

    This concept of assay multiplexing is demonstrated here using several cell-based assays multiplexed together. There are inherent properties to cell assays that make them attractive for multiplexed cell-based applications. Cell-based assays are especially vulnerable to variations due to differences in cell growth and metabolism that can arise from plate-to-plate. Cell culture itself is also expensive. By multiplexing assays, fewer cells are needed to acquire the same amount of data. Using the same cells for subsequent assays can also ensure more precise data. In this applicat ion note, we demonstrate the combination of several Promega cell-based assays multiplexed in both low-volume 384- and 1536-well plate formats. The BMG LABTECH PHERAstar microplate reader is used to record luminescence. Table 1 highlights the assays used in this application.

    Materials and Methods

  • HEK293 cells stably transfected with a CRE/CL1 hPEST Renilla construct
  • Isoproterenol
  • Corning Low-volume 384-well plates, catalog no. 3673
  • Corning 1536-well plates, catalog no. 3937
  • Promega CellTiter-Glo Luminescent Cell Viability Assay, catalog no. G7570*
  • Promega EnduRen Live Cell Substrate, catalog no. E6482*
  • Promega ViviRen Live Cell Substrate, catalog no. E6492*
  • Deerac Fluidics Equator HTS low-volume liquid dispenser
  • BMG LABTECH PHERAstar (figure 1)
  • BMG LABTECH PHERAstar luminescence optic module

  • Multiplexing Luciferase Reporter and Cell Viability Assays
    Promegas luminescent CellTiter-Glo assay was multiplexed with either the luminescent EnduRen Live Cell Substrate, or the luminescent ViviRen Live Cell Substrate. The experimental set-up was similar for each assay combination.

    For the low-volume 384 assay format, a density of 12,000 stably transfected HEK 293 cells per well was plated with the Deerac Fluidics Equator. Cells were allowed to attach for 10 hours at 37C / 10% CO2. EnduRen Live Cell Substrate was added by the Equator to one plate of cells at a final concentration of 60 M and allowed to incubate with the cells for 2 hours at 37C / 10% CO2. 10 M of isoproterenol was added to all test plates to induce CRE. Induction was monitored at 0, 1-, 2-, 3-, and 5-hour time points. At each time point, ViviRen substrate was added by the Equator at a final concentration of 60 M, luminescence reporter signal was recorded, followed by addition of the CellTiter-Glo reagent by the Equator. Luminescence was recorded a second time to measure ATP content and cell number.

    For the 1536-well assay format, a density of 4,000 stably transfected HEK 293 cells per well was plated with the Deerac Fluidics Equator. The remaining multiplex protocols were performed identically to the low-volume 384 protocols listed above.

    Results and Discussion
    To correlate Renilla luciferase reporter gene signal for cell viability, Promegas CellTiter-Glo assay was multiplexed with either the EnduRen Live Cell Substrate or the ViviRen Live Cell Substrate. Both multiplexed assay combinations were prepared in both low-volume 384- and 1536-well format and Renilla expression and cell viability were sequentially measured with BMG LABTECHs PHERAstar in luminsecence mode (figure 2 and figure 3).

    HEK 293 cells were treated with isoproterenol for 5 hours to induce Renilla reporter expression and a correlated kinetic profile of the reporter signal and cell viability were recorded over this time. The EnduRen Live Cell Substrate was added 2 hours before CRE induction and allowed to incubate with the cells. The ViviRen Live Cell Substrate was added directly before each measurement point. After luminescence reporter signal determination, the CellTiter-Glo reagent was added at each measurement point to inactivate Reni lla luminescence and initiate ATP-dependent luminescence, which was recorded to measure the cell viability.

    When making correlations between experimental conditions and the expression of a reporter gene, other events associated with cell physiology may affect reporter gene expression. Using live cell reporter substrates, it is possible to track the response of a Renilla reporter in real time by measuring luminescent Renilla reporter activity. Including a cell viability assay allows one to correlate reporter response with overall cell number. For this application, the Renilla reporter expression was optimal at 3 hours of treatment with 10 M isoproterenol in both assay formats tested, regardless of which substrate was used. Cell viability did not change over the time tested, indicating that changes in reporter response were due to the treatment and not changes in cell number. Using the same experimental conditions, the results also show the increased luminescence generated by the ViviRen substrate over the EnduRen substrate. The ViviRen substrate would be a good option when using cell lines that are weakly expressing Renilla luciferase, or for instances when fewer cells are being used as is the case for 1536-well format. Low volume 384 results also correlate with those in 1536, suggesting that miniaturization of these assays does not compromise data quality.

    Multiplexed cell-based assays allow for multiple parameters to be measured within the same well. With reporter assays, the expression of a luciferase reporter can be greatly affected by the overall health of the cell. By multiplexing a reporter a ssay with a cell viability assay, it is possible to determine if reporter response variations are due to changes in cell number and health. Depending on the Renilla expression levels or the number of cells being used, the EnduRen and ViviRen Live Cell Substrates provide options for the customer looking to observe real-time reporter kinetics. The sensitivity of the PHERAstar allowed for luminescence detection from both reporter substrates. The data generated here also showcases the ability of BMG LABTECHs PHERAstar to record luminescence from microplates of different well densities up to 1536-wells.

    * See Promegas website for patent marking information

    back to top



    Page: All 1 2 3 4 5

    Related biology technology :

    1. Promegas Multiplexed Cell Viability and Apoptosis Assays performed on the PHERAstar
    2. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
    3. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
    4. Dual-Luciferase Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #39)
    5. Luciferase Reporter Gene Cells and Recombinant Luciferase Dilutions Studied with the CLIPR Luciferase Assay Kit and the LMax Microplate Luminometer (MaxLine Application Note #38)
    6. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
    7. Versatile Reporter Vectors for Monitoring Viral Transduction
    8. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
    9. Genetic Reporter Systems
    10. Genetic Reporter Systems
    11. Detection of Reporter Gene Activity in Cell Cultures and Murine Epidermis After Helios Gene Gun-Mediated Particle Bombardment
    Post Your Comments:

    (Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
    (Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
    (Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
    (Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
    Breaking Biology Technology:
    (Date:10/29/2015)... 2015 NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... a leading marketplace to discover and buy innovative ... wallet on StackSocial for this holiday season.   ... "Company"), a biometric authentication company focused on the ...
    (Date:10/26/2015)... , October 26, 2015 ... --> adds Biometrics Market ... 2021 as well as Emerging Biometrics ... reports to its collection of IT ... . --> ...
    (Date:10/22/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software and ... 30, 2015.  --> --> ... decrease of 33% compared to $6.0 million in the same quarter ... $2.2 million, or $0.10 per diluted share, which compared to $2.6 ... year ago.  --> --> ...
    Breaking Biology News(10 mins):